Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • 2025
  • Page 116
dr.-reddy’s-pens-$370m-pact-for-rights-to-immutep’s-phase-3-stage-immunotherapy-in-certain-markets
Posted inBiotechnology

Dr. Reddy’s pens $370M pact for rights to Immutep’s phase 3-stage immunotherapy in certain markets

December 8, 2025
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories…
Read More
gut-microbe-molecule-reduces-inflammation-and-improves-blood-sugar-control
Posted inGenetics

Gut Microbe Molecule Reduces Inflammation and Improves Blood Sugar Control

December 8, 2025
Trimethylamine (TMA), a molecule produced from dietary choline by gut bacteria, has been shown to block a key immune pathway…
Read More
with-weight-loss-windfall,-lilly-looks-to-become-‘backbone’-of-global-innovation:-exec
Posted inBiotechnology

With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec

December 8, 2025
With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli Lilly…
Read More
wave,-structure-stocks-double-on-obesity-data-readouts
Posted inBiotechnology

Wave, Structure stocks double on obesity data readouts

December 8, 2025
Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set…
Read More
mirum-beckons-bluejay-and-its-phase-3-stage-hepatitis-drug-for-$620m
Posted inBiotechnology

Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M

December 8, 2025
Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug.…
Read More
stryker-promotes-new-president,-coo-to-help-lead-its-m&a-strategy
Posted inMedical Technology

Stryker promotes new president, COO to help lead its M&A strategy

December 8, 2025
Stryker, with its eye on tuck-in acquisitions and streamlining its business core, has promoted 27-year veteran Spencer Stiles to president…
Read More
biontech’s-ctla-4-drug-improves-survival-in-phase-3-cancer-trial-but-poses-tolerability-challenge
Posted inBiotechnology

BioNTech’s CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge

December 8, 2025
A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts…
Read More
china’s-ascletis-reports-7.7%-weight-loss-for-oral-glp-1-contender-in-us-phase-2-study
Posted inBiotechnology

China’s Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study

December 8, 2025
Ascletis Pharma has posted 7.7% weight loss for the highest dose of its own entrant in the highly contested oral…
Read More
abbvie-hands-back-phase-1-duties-for-chronic-inflammation-drug-to-partner-ose
Posted inBiotechnology

AbbVie hands back phase 1 duties for chronic inflammation drug to partner Ose

December 8, 2025
Close to two years after AbbVie handed over $48 million for the rights to Ose Immunotherapeutics’ inflammation drug, the Big…
Read More
stockwatch:-cosmo-surges-40%-on-baldness-candidate’s-phase-iii-data
Posted inGenetics

StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data

December 8, 2025
Images of the scalps of two patients treated with the 5% formulation of Cosmo Pharmaceuticals’ androgenetic alopecia (AGA) candidate clascoterone—both…
Read More

Posts pagination

Previous page 1 … 114 115 116 117 118 … 1,169 Next page

Privacy Policy    Terms

Scroll to Top